A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.
Comparing Continuous BTK Inhibitors in Treatment-Naive CLL
Talha Munir, MBChB, PhD, discusses the implications of an MAIC comparing zanubrutinib and ibrutinib in treatment-naive CLL.
Advertisement
Advertisement
Trending on OncLive
1
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas
2
Tacabrutideg Is Tolerable and Shows Efficacy Signals Across BTK Inhibitor–Naive CLL and Other B-Cell Malignancies
3
Subcutaneous Blinatumomab Yields High Efficacy Rates in R/R Ph+ B-ALL
4
Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026
5